Thyroid cancer is the most common form of endocrine malignancy and its incidence is increasing. Thyroid cancers usually present as painless nodules found upon palpation, and nodules >1 cm should be evaluated as they have a higher potential for being clinically significant cancers.
Papillary thyroid cancer is the most prevalent thyroid cancer, accounting for 80% of thyroid cancer diagnoses. Prognosis is good for patients with early and aggressive treatment, and the new and emerging therapies targeting the RET pathway may improve outcomes for patients with advanced disease.
Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care
The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum.
NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer
In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation.
Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer
A review of the National Cancer Database reveals that use of neoadjuvant chemotherapy for advanced epithelial ovarian cancer increased markedly between 2004 and 2016. At the same time, median survival improved by more than 6 months. Study authors found no association between the 2 trends.
Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months
Page 3 of 36
Results 21 - 30 of 356
Results 21 - 30 of 356